In a study published in Nature, the team found that microglia with lower levels of a transcription factor called PU.1 and ...

Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...

GAITHERSBURG, Md., US, November 7, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative ...

Researchers have identified special immune cells in the brain that help slow Alzheimer's disease. These microglia work to ...

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with ...

A promising breakthrough in autoimmune disease research may open the door to safer and more effective treatments. Scientists ...

Researchers have identified special immune cells in the brain that help slow Alzheimer's disease. These microglia work to reduce inflammation and block the spread of harmful proteins. They appear to ...

Researchers have identified special immune cells in the brain that help slow Alzheimer’s. These microglia work to reduce inflammation and block the spread of harmful proteins. They appear to protect ...

CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory systemic sclerosis, with 96% remaining off SSc treatment during follow-up, ...

The first patient has been dosed in a Phase 1 trial testing the experimental CAR T-cell therapy obecabtagene autoleucel for progressive MS.